Tyrphostin AG490 Agent Modestly but Significantly Prevents Onset of Type 1 in NOD Mouse; Implication of Immunologic and Metabolic Effects of a Jak-Stat Pathway Inhibitor
- 333 Downloads
Previously, we have reported that the Jak-Stat signaling pathway is defective in NOD mice. In this study, prediabetic female NOD mice (4 weeks) were treated by intraperitoneal injection either with AG490 or DMSO three times per week for 4 consecutive weeks, followed by once a week for an additional 6 weeks. The onset of diabetes was attenuated in NOD mice treated with AG490 relative to DMSO treated control mice (p < 0.02). From an immunological standpoint, AG490 induced the expression of Foxp3 in CD4+CD25− T-cells and down-regulated expression of co-stimulatory molecules in dendritic cells (DC) both in vitro and in vivo. AG490 treated CD4+CD25− T-cells and DC in vitro, acquired regulatory functions; namely, the ability to suppress proliferation of a responding cell population in vitro. AG490 treatment resulted in significant reduction of blood glucose values and increased expression of PPARγ in splenocytes and markedly increased expression PPARγ2 but not PPARγ1 in adipocyte in vitro. Presence of multiple Stat5 DNA binding consensus sequences within the promoter region of the PPARγ gene in human and in mouse suggests that PPARγ is downstream to the Jak-Stat signaling pathway. This study highlights a critical role of the Jak-Stat signaling pathway in the pathogenesis of T1D and suggests that blocking the Jak-Stat signaling pathway by AG490 as a tyrosine kinase inhibitor may provide an effective means for preventing autoimmune T1D via both immunological and metabolic effects.
KeywordsType 1 diabetes tyrosine kinase inhibitor AG490 regulatory T-cell NOD
This work was supported by Juvenile Diabetes Research Foundation International (JDRFI) (JDRF#5-2006-937) and by NIH grant, The American Recovery And Reinvestment Act, (R21AI076394) awarded to ADS.
The authors have no financial conflicts of interest.
- 1.Augstein P, Dunger A, Heinke P, Wachlin G, Berg S, Hehmke B, Salzsieder E. Prevention of autoimmune diabetes in NOD mice by troglitazone is associated with modulation of ICAM-1 expression on pancreatic islet cells and IFN-gamma expression in splenic T cells. Biochem Biophys Res Commun. 2003;304:378–84.PubMedCrossRefGoogle Scholar
- 7.Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, Rizzuti BJ, Sawyer PS, Perry BD, Brissette WH, McCurdy SP, Kudlacz EM, Conklyn MJ, Elliott EA, Koslov ER, Fisher MB, Strelevitz TJ, Yoon K, Whipple DA, Sun J, Munchhof MJ, Doty JL, Casavant JM, Blumenkopf TA, Hines M, Brown MF, Lillie BM, Subramanyam C, Shang-Poa C, Milici AJ, Beckius GE, Moyer JD, Su C, Woodworth TG, Gaweco AS, Beals CR, Littman BH, Fisher DA, Smith JF, Zagouras P, Magna HA, Saltarelli MJ, Johnson KS, Nelms LF, Des Etages SG, Hayes LS, Kawabata TT, Finco-Kent D, Baker DL, Larson M, Si MS, Paniagua R, Higgins J, Holm B, Reitz B, Zhou YJ, Morris RE, O’Shea JJ, Borie DC. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003;302:875–8.PubMedCrossRefGoogle Scholar
- 8.Chauhan G, Spurgeon CJ, Tabassum R, Bhaskar S, Kulkarni SR, Mahajan A, Chavali S, Kumar MV, Prakash S, Dwivedi OP, Ghosh S, Yajnik CS, Tandon N, Bharadwaj D, Chandak GR. Impact of common variants of PPARG, KCNJ11, TCF7L2, SLC30A8, HHEX, CDKN2A, IGF2BP2, and CDKAL1 on the risk of type 2 diabetes in 5,164 Indians. Diabetes. 2010;59:2068–74.PubMedCrossRefGoogle Scholar
- 11.Crespo O, Kang SC, Daneman R, Lindstrom TM, Ho PP, Sobel RA, Steinman L, Robinson WH. Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis. J. Clin. Immunol. 2011Google Scholar
- 13.Davoodi-Semiromi A, McDuffie M, Litherland S, Clare-Salzler M. Truncated pStat5B is associated with the Idd4 locus in NOD mice. Biochem Biophys Res Commun. 2007;11;356(3):655–61.Google Scholar
- 14.Davoodi-Semiromi A, Cheikhi A, Xia C, Litherland S, Clare-Salzler M. Modulation of CD4+Foxp3- T-cells with a JAK-STAT5 kinase inhibitor. J Immunol. 2007;178:S237–c.Google Scholar
- 15.Davoodi-Semiromi A, Copper-DeHoff R. Note to readers on: long term treatment with ACE inhibitor enalapril decreases body weight gain and increases life span in rats. Biochem. Pharmacol. Biochem Pharmacol. 2012;15;83(6):821.Google Scholar
- 17.Eriksen KW, Kaltoft K, Mikkelsen G, Nielsen M, Zhang Q, Geisler C, Nissen MH, Ropke C, Wasik MA, Odum N. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia. 2001;15:787–93.PubMedCrossRefGoogle Scholar
- 19.Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, Warner JD, Tanaka M, Steward-Tharp SM, Gadina M, Thomas CJ, Minnerly JC, Storer CE, LaBranche TP, Radi ZA, Dowty ME, Head RD, Meyer DM, Kishore N, O’Shea JJ. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186:4234–43.PubMedCrossRefGoogle Scholar
- 34.Sidhu M, Cotoner CA, Guleng B, Arihiro S, Chang S, Duncan KW, Ajami AM, Chau M, Reinecker HC. Small molecule tyrosine kinase inhibitors for the treatment of intestinal inflammation. Inflamm. Bowel. Dis. 2011Google Scholar
- 39.Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, Ang J, Temple G, Bell S, Shahidi M, Uttenreuther-Fischer M, Stopfer P, Futreal A, Calvert H, de Bono JS, Plummer R. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol. 2010;28:3965–72.PubMedCrossRefGoogle Scholar